Pamela Coxson, PhD

Specialist

Publications
  1. Konfino J, Salgado MV, Penko J, Coxson P, Fernández A, Pichon-Riviere A, Bibbins-Domingo K, Mejía R. Impacto sanitario de la prohibición total de publicidades de tabaco en argentina. 2022. PMID: 35440241


  2. Kazi DS, Wei PC, Penko J, Bellows BK, Coxson P, Bryant KB, Fontil V, Blyler CA, Lyles C, Lynch K, Ebinger J, Zhang Y, Tajeu GS, Boylan R, Pletcher MJ, Rader F, Moran AE, Bibbins-Domingo K. Scaling Up Pharmacist-Led Blood Pressure Control Programs in Black Barbershops: Projected Population Health Impact and Value. 2021. PMID: 34125566


  3. Bryant KB, Moran AE, Kazi DS, Zhang Y, Penko J, Ruiz-Negrón N, Coxson P, Blyler CA, Lynch K, Cohen LP, Tajeu GS, Fontil V, Moy NB, Ebinger JE, Rader F, Bibbins-Domingo K, Bellows BK. Cost-effectiveness of Hypertension Treatment by Pharmacists in Black Barbershops. 2021. PMID: 33855861


  4. Hamad R, Penko J, Kazi DS, Coxson P, Guzman D, Wei PC, Mason A, Wang EA, Goldman L, Fiscella K, Bibbins-Domingo K. Association of Low Socioeconomic Status With Premature Coronary Heart Disease in US Adults. 2020. PMID: 32459344


  5. Salgado MV, Penko J, Fernandez A, Konfino J, Coxson PG, Bibbins-Domingo K, Mejia R. Projected impact of a reduction in sugar-sweetened beverage consumption on diabetes and cardiovascular disease in Argentina: A modeling study. 2020. PMID: 32722677


  6. Medina C, Coxson P, Penko J, Janssen I, Bautista-Arredondo S, Barquera S, Bibbins-Domingo K. Cardiovascular and diabetes burden attributable to physical inactivity in Mexico. 2020. PMID: 32600339


  7. Williams BA, Li A, Ahalt C, Coxson P, Kahn JG, Bibbins-Domingo K. The Cardiovascular Health Burdens of Solitary Confinement. 2019. PMID: 31228050


  8. Kazi DS, Penko J, Coxson PG, Guzman D, Wei PC, Bibbins-Domingo K. Cost-Effectiveness of Alirocumab: A Just-in-Time Analysis Based on the ODYSSEY Outcomes Trial. 2019. PMID: 30597485


  9. Salgado MV, Coxson P, Konfino J, Penko J, Irazola VE, Gutiérrez L, Fernández A, Mejía R. Update of the cardiovascular disease policy model to predict cardiovascular events in Argentina. 2019. PMID: 31829945


  10. Kazi DS, Penko J, Ollendorf DA, Coxson PG, Bibbins-Domingo K. Effect of Money-Back Guarantees on the Cost-Effectiveness of Proprotein Convertase Subtilisin/Kexin Type 9 Inhibitors. 2018. PMID: 29610832


  11. Huang C, Moran AE, Coxson PG, Yang X, Liu F, Cao J, Chen K, Wang M, He J, Goldman L, Zhao D, Kinney PL, Gu D. Potential Cardiovascular and Total Mortality Benefits of Air Pollution Control in Urban China. Volume 136 of Issue 17. 2017. PMID: 28882886


  12. Kazi DS, Penko J, Coxson PG, Moran AE, Ollendorf DA, Tice JA, Bibbins-Domingo K. Updated Cost-effectiveness Analysis of PCSK9 Inhibitors Based on the Results of the FOURIER Trial. 2017. PMID: 28829863


  13. Heller DJ, Coxson PG, Penko J, Pletcher MJ, Goldman L, Odden MC, Kazi DS, Bibbins-Domingo K. Evaluating the Impact and Cost-Effectiveness of Statin Use Guidelines for Primary Prevention of Coronary Heart Disease and Stroke. 2017. PMID: 28687710


  14. Konfino J, Fernandez A, Penko J, Mason A, Martinez E, Coxson P, Heller D, Moran A, Bibbins-Domingo K, Pérez-Stable EJ, Mejía R. Comparing Strategies for Lipid Lowering in Argentina: An Analysis from the CVD Policy Model-Argentina. 2016. PMID: 27853916


  15. Sánchez-Romero LM, Penko J, Coxson PG, Fernández A, Mason A, Moran AE, Ávila-Burgos L, Odden M, Barquera S, Bibbins-Domingo K. Projected Impact of Mexico's Sugar-Sweetened Beverage Tax Policy on Diabetes and Cardiovascular Disease: A Modeling Study. 2016. PMID: 27802278


  16. Kazi DS, Moran AE, Coxson PG, Penko J, Ollendorf DA, Pearson SD, Tice JA, Guzman D, Bibbins-Domingo K. Cost-effectiveness of PCSK9 Inhibitor Therapy in Patients With Heterozygous Familial Hypercholesterolemia or Atherosclerotic Cardiovascular Disease. 2016. PMID: 27533159


  17. Moise N, Huang C, Rodgers A, Kohli-Lynch CN, Tzong KY, Coxson PG, Bibbins-Domingo K, Goldman L, Moran AE. Comparative Cost-Effectiveness of Conservative or Intensive Blood Pressure Treatment Guidelines in Adults Aged 35-74 Years: The Cardiovascular Disease Policy Model. 2016. PMID: 27181996


  18. Vasudeva E, Moise N, Huang C, Mason A, Penko J, Goldman L, Coxson PG, Bibbins-Domingo K, Moran AE. Comparative Cost-Effectiveness of Hypertension Treatment in Non-Hispanic Blacks and Whites According to 2014 Guidelines: A Modeling Study. 2016. PMID: 27172970


  19. Odden MC, Moran AE, Coxson PG, Peralta CA, Goldman L, Bibbins-Domingo K. Gait Speed as a Guide for Blood Pressure Targets in Older Adults: A Modeling Study. 2016. PMID: 27225357


  20. Wang M, Moran AE, Liu J, Coxson PG, Penko J, Goldman L, Bibbins-Domingo K, Zhao D. Projected Impact of Salt Restriction on Prevention of Cardiovascular Disease in China: A Modeling Study. 2016. PMID: 26840409


  21. Gu D, He J, Coxson PG, Rasmussen PW, Huang C, Thanataveerat A, Tzong KY, Xiong J, Wang M, Zhao D, Goldman L, Moran AE. The Cost-Effectiveness of Low-Cost Essential Antihypertensive Medicines for Hypertension Control in China: A Modelling Study. Volume 12 of Issue 8. 2015. PMID: 26241895


  22. Odden MC, Pletcher MJ, Coxson PG, Thekkethala D, Guzman D, Heller D, Goldman L, Bibbins-Domingo K. Cost-effectiveness and population impact of statins for primary prevention in adults aged 75 years or older in the United States. 2015. PMID: 25894023


  23. Fontil V, Bibbins-Domingo K, Kazi DS, Sidney S, Coxson PG, Khanna R, Victor RG, Pletcher MJ. Simulating Strategies for Improving Control of Hypertension Among Patients with Usual Source of Care in the United States: The Blood Pressure Control Model. 2015. PMID: 25749880


  24. Moran AE, Odden MC, Thanataveerat A, Tzong KY, Rasmussen PW, Guzman D, Williams L, Bibbins-Domingo K, Coxson PG, Goldman L. Cost-effectiveness of hypertension therapy according to 2014 guidelines. 2015. PMID: 25629742


  25. Wang M, Moran AE, Liu J, Coxson PG, Heidenreich PA, Gu D, He J, Goldman L, Zhao D. Cost-effectiveness of optimal use of acute myocardial infarction treatments and impact on coronary heart disease mortality in China. Volume 7 of Issue 1. 2014. PMID: 24425706


  26. Mekonnen TA, Odden MC, Coxson PG, Guzman D, Lightwood J, Wang YC, Bibbins-Domingo K. Health benefits of reducing sugar-sweetened beverage intake in high risk populations of California: results from the cardiovascular disease (CVD) policy model. 2013. PMID: 24349119


  27. Konfino J, Mekonnen TA, Coxson PG, Ferrante D, Bibbins-Domingo K. Projected impact of a sodium consumption reduction initiative in Argentina: an analysis from the CVD policy model--Argentina. 2013. PMID: 24040085


  28. Coxson PG, Cook NR, Joffres M, Hong Y, Orenstein D, Schmidt SM, Bibbins-Domingo K. Mortality benefits from US population-wide reduction in sodium consumption: projections from 3 modeling approaches. 2013. PMID: 23399718


  29. Konfino J, Ferrante D, Mejia R, Coxson P, Moran A, Goldman L, Pérez-Stable EJ. Impact on cardiovascular disease events of the implementation of Argentina's national tobacco control law. Volume 23 of Issue 2. 2012. PMID: 23092886


  30. Ferrante D, Konfino J, Mejía R, Coxson P, Moran A, Goldman L, Pérez-Stable EJ. [The cost-utility ratio of reducing salt intake and its impact on the incidence of cardiovascular disease in Argentina]. Volume 32 of Issue 4. 2012. PMID: 23299288


  31. Chan F, Adamo S, Coxson P, Goldman L, Gu D, Zhao D, Chen CS, He J, Mara V, Moran A. Projected impact of urbanization on cardiovascular disease in China. Volume 57 of Issue 5. 2012. PMID: 22918518


  32. Wang YC, Coxson P, Shen YM, Goldman L, Bibbins-Domingo K. A penny-per-ounce tax on sugar-sweetened beverages would cut health and cost burdens of diabetes. 2012. PMID: 22232111


  33. Galper BZ, Moran A, Coxson PG, Pletcher MJ, Heidenreich P, Lazar LD, Rodondi N, Wang YC, Goldman L. Using stress testing to guide primary prevention of coronary heart disease among intermediate-risk patients: a cost-effectiveness analysis. Volume 125 of Issue 2. 2011. PMID: 22144567


  34. Odden MC, Coxson PG, Moran A, Lightwood JM, Goldman L, Bibbins-Domingo K. The impact of the aging population on coronary heart disease in the United States. 2011. PMID: 21722862


  35. Lazar LD, Pletcher MJ, Coxson PG, Bibbins-Domingo K, Goldman L. Cost-effectiveness of statin therapy for primary prevention in a low-cost statin era. 2011. PMID: 21709063


  36. Moran A, Degennaro V, Ferrante D, Coxson PG, Palmas W, Mejia R, Perez-Stable EJ, Goldman L. Coronary heart disease and stroke attributable to major risk factors is similar in Argentina and the United States: the Coronary Heart Disease Policy Model. Volume 150 of Issue 3. 2011. PMID: 21550675


  37. Victor RG, Ravenell JE, Freeman A, Leonard D, Bhat DG, Shafiq M, Knowles P, Storm JS, Adhikari E, Bibbins-Domingo K, Coxson PG, Pletcher MJ, Hannan P, Haley RW. Effectiveness of a barber-based intervention for improving hypertension control in black men: the BARBER-1 study: a cluster randomized trial. 2010. PMID: 20975012


  38. Pletcher MJ, Coxson PG. Does age modify effectiveness of statin therapy in coronary artery disease? Volume 152 of Issue 12. 2010. PMID: 20547915


  39. Moran A, Gu D, Zhao D, Coxson P, Wang YC, Chen CS, Liu J, Cheng J, Bibbins-Domingo K, Shen YM, He J, Goldman L. Future cardiovascular disease in china: markov model and risk factor scenario projections from the coronary heart disease policy model-china. 2010. PMID: 20442213


  40. Bibbins-Domingo K, Chertow GM, Coxson PG, Moran A, Lightwood JM, Pletcher MJ, Goldman L. Projected effect of dietary salt reductions on future cardiovascular disease. 2010. PMID: 20089957


  41. Lightwood J, Bibbins-Domingo K, Coxson P, Wang YC, Williams L, Goldman L. Forecasting the future economic burden of current adolescent overweight: an estimate of the coronary heart disease policy model. 2009. PMID: 19833999


  42. Pletcher MJ, Lazar L, Bibbins-Domingo K, Moran A, Rodondi N, Coxson P, Lightwood J, Williams L, Goldman L. Comparing impact and cost-effectiveness of primary prevention strategies for lipid-lowering. 2009. PMID: 19221376


  43. Lightwood JM, Coxson PG, Bibbins-Domingo K, Williams LW, Goldman L. Coronary heart disease attributable to passive smoking: CHD Policy Model. 2009. PMID: 19095162


  44. Moran A, Zhao D, Gu D, Coxson P, Chen CS, Cheng J, Liu J, He J, Goldman L. The future impact of population growth and aging on coronary heart disease in China: projections from the Coronary Heart Disease Policy Model-China. Volume 8. 2008. PMID: 19036167


  45. Bibbins-Domingo K, Coxson P, Pletcher MJ, Lightwood J, Goldman L. Adolescent overweight and future adult coronary heart disease. 2007. PMID: 18057339


  46. Gaspoz JM, Coxson PG, Goldman PA, Williams LW, Kuntz KM, Hunink MG, Goldman L. Cost effectiveness of aspirin, clopidogrel, or both for secondary prevention of coronary heart disease. Volume 346 of Issue 23. 2002. PMID: 12050341